Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
Ulrike Wille-Reece, Barbara J Flynn, Karin Loré, Richard A Koup, Aaron P Miles, Allan Saul, Ross M Kedl, Joseph J Mattapallil, Walter R Weiss, Mario Roederer, Robert A Seder, Ulrike Wille-Reece, Barbara J Flynn, Karin Loré, Richard A Koup, Aaron P Miles, Allan Saul, Ross M Kedl, Joseph J Mattapallil, Walter R Weiss, Mario Roederer, Robert A Seder
Abstract
There is a remarkable heterogeneity in the functional profile (quality) of T cell responses. Importantly, the magnitude and/or quality of a response required for protection may be different depending on the infection. Here, we assessed the capacity of different Toll like receptor (TLR)-binding compounds to influence T helper cell (Th)1 and CD8+ T cell responses when used as adjuvants in nonhuman primates (NHP) with HIV Gag as a model antigen. NHP were immunized with HIV Gag protein emulsified in Montanide ISA 51, an oil-based adjuvant, with or without a TLR7/8 agonist, a TLR8 agonist, or the TLR9 ligand cytosine phosphate guanosine oligodeoxynucleotides (CpG ODN), and boosted 12 wk later with a replication-defective adenovirus-expressing HIV-Gag (rAD-Gag). Animals vaccinated with HIV Gag protein/Montanide and CpG ODN or the TLR7/8 agonist had higher frequencies of Th1 responses after primary immunization compared to all other vaccine groups. Although the rAD-Gag boost did not elevate the frequency of Th1 memory cytokine responses, there was a striking increase in HIV Gag-specific CD8+ T cell responses after the boost in all animals that had received a primary immunization with any of the TLR adjuvants. Importantly, the presence and type of TLR adjuvant used during primary immunization conferred stability and dramatically influenced the magnitude and quality of the Th1 and CD8+ T cell responses after the rAD-Gag boost. These data provide insights for designing prime-boost immunization regimens to optimize Th1 and CD8+ T cell responses.
Figures
References
- Seder, R.A., and A.V. Hill. 2000. Vaccines against intracellular infections requiring cellular immunity. Nature. 406:793–798.
- Baba, T.W., Y.S. Jeong, D. Pennick, R. Bronson, M.F. Greene, and R.M. Ruprecht. 1995. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science. 267:1820–1825.
- Shiver, J.W., T.M. Fu, L. Chen, D.R. Casimiro, M.E. Davies, R.K. Evans, Z.Q. Zhang, A.J. Simon, W.L. Trigona, S.A. Dubey, et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415:331–335.
- Seaman, M.S., L. Xu, K. Beaudry, K.L. Martin, M.H. Beddall, A. Miura, A. Sambor, B.K. Chakrabarti, Y. Huang, R. Bailer, et al. 2005. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol. 79:2956–2963.
- Donnelly, J.J., B. Wahren, and M.A. Liu. 2005. DNA vaccines: progress and challenges. J. Immunol. 175:633–639.
- Casimiro, D.R., L. Chen, T.M. Fu, R.K. Evans, M.J. Caulfield, M.E. Davies, A. Tang, M. Chen, L. Huang, V. Harris, et al. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:6305–6313.
- Santra, S., M.S. Seaman, L. Xu, D.H. Barouch, C.I. Lord, M.A. Lifton, D.A. Gorgone, K.R. Beaudry, K. Svehla, B. Welcher, et al. 2005. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 79:6516–6522.
- Wille-Reece, U., B.J. Flynn, K. Lore, R.A. Koup, R.M. Kedl, J.J. Mattapallil, W.R. Weiss, M. Roederer, and R.A. Seder. 2005. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl. Acad. Sci. USA. 102:15190–15194.
- Aucouturier, J., L. Dupuis, S. Deville, S. Ascarateil, and V. Ganne. 2002. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines. 1:111–118.
- Pitcher, C.J., S.I. Hagen, J.M. Walker, R. Lum, B.L. Mitchell, V.C. Maino, M.K. Axthelm, and L.J. Picker. 2002. Development and homeostasis of T cell memory in rhesus macaque. J. Immunol. 168:29–43.
- Wherry, E.J., V. Teichgraber, T.C. Becker, D. Masopust, S.M. Kaech, R. Antia, U.H. von Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4:225–234.
- Vaccari, M., C.J. Trindade, D. Venzon, M. Zanetti, and G. Franchini. 2005. Vaccine-induced CD8+ central memory T cells in protection from simian AIDS. J. Immunol. 175:3502–3507.
- Ahlers, J.D., N. Dunlop, C.D. Pendleton, M. Newman, P.L. Nara, and J.A. Berzofsky. 1996. Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization. AIDS Res. Hum. Retroviruses. 12:259–272.
- Kumar, S., T.R. Jones, M.S. Oakley, H. Zheng, S.P. Kuppusamy, A. Taye, A.M. Krieg, A.W. Stowers, D.C. Kaslow, and S.L. Hoffman. 2004. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect. Immun. 72:949–957.
- Speiser, D.E., D. Lienard, N. Rufer, V. Rubio-Godoy, D. Rimoldi, F. Lejeune, A.M. Krieg, J.C. Cerottini, and P. Romero. 2005. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115:739–746.
- Wu, C.Y., J.R. Kirman, M.J. Rotte, D.F. Davey, S.P. Perfetto, E.G. Rhee, B.L. Freidag, B.J. Hill, D.C. Douek, and R.A. Seder. 2002. Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat. Immunol. 3:852–858.
- Sun, J.C., M.A. Williams, and M.J. Bevan. 2004. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat. Immunol. 5:927–933.
- Sun, J.C., and M.J. Bevan. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 300:339–342.
- Shedlock, D.J., and H. Shen. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 300:337–339.
- Zimmerli, S.C., A. Harari, C. Cellerai, F. Vallelian, P.A. Bart, and G. Pantaleo. 2005. HIV-1-specific IFN-γ/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc. Natl. Acad. Sci. USA. 102:7239–7244.
- Lichterfeld, M., D.E. Kaufmann, X.G. Yu, S.K. Mui, M.M. Addo, M.N. Johnston, D. Cohen, G.K. Robbins, E. Pae, G. Alter, et al. 2004. Loss of HIV-1–specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1–specific CD4+ T cells. J. Exp. Med. 200:701–712.
- Migueles, S.A., A.C. Laborico, W.L. Shupert, M.S. Sabbaghian, R. Rabin, C.W. Hallahan, D. Van Baarle, S. Kostense, F. Miedema, M. McLaughlin, et al. 2002. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3:1061–1068.
- Younes, S.A., B. Yassine-Diab, A.R. Dumont, M.R. Boulassel, Z. Grossman, J.P. Routy, and R.P. Sekaly. 2003. HIV-1 viremia prevents the establishment of interleukin 2–producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 198:1909–1922.
- Harari, A., S. Petitpierre, F. Vallelian, and G. Pantaleo. 2004. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood. 103:966–972.
- Miles, A.P., H.A. McClellan, K.M. Rausch, D. Zhu, M.D. Whitmore, S. Singh, L.B. Martin, Y. Wu, B.K. Giersing, A.W. Stowers, et al. 2005. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine. 23:2530–2539.
- Gorden, K.B., K.S. Gorski, S.J. Gibson, R.M. Kedl, W.C. Kieper, X. Qiu, M.A. Tomai, S.S. Alkan, and J.P. Vasilakos. 2005. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR 8. J. Immunol. 174:1259–1268.
- Betts, M.R., M.C. Nason, S.M. West, S.C. DeRosa, S.A. Migueles, J. Abraham, M.M. Lederman, J.M. Benito, P.A. Goepfert, M. Connors, M. Roederer, and R.A. Koup. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. In press.
Source: PubMed